Immune checkpoints inhibitors rechallenge in non-small-cell lung cancer: different scenarios with different solutions?
作者信息
Metro Giulio, Signorelli Diego
机构信息
Medical Oncology, Santa Maria della Misericordia Hospital, Azienda Ospedaliera di Perugia, Perugia, Italy.
Medical Oncology Department, Fondazione IRCCS, Istituto Nazionale Tumori di Milano, Milano, Italy.
出版信息
Lung Cancer Manag. 2020 Jan 16;8(4):LMT18. doi: 10.2217/lmt-2019-0012.
Abstract
摘要
相似文献
1
Immune checkpoints inhibitors rechallenge in non-small-cell lung cancer: different scenarios with different solutions?非小细胞肺癌中免疫检查点抑制剂的再挑战：不同情况有不同解决方案？
Lung Cancer Manag. 2020 Jan 16;8(4):LMT18. doi: 10.2217/lmt-2019-0012.
2
Rechallenge of immune checkpoint inhibitors in advanced non-small cell lung cancer.晚期非小细胞肺癌中免疫检查点抑制剂的再挑战。
Thorac Cancer. 2024 Feb;15(5):419-426. doi: 10.1111/1759-7714.15209. Epub 2024 Jan 14.
3
Efficacy of rechallenge immunotherapy after immune monotherapy resistance in patients with advanced non-small cell lung cancer.免疫单药治疗耐药后再次挑战免疫治疗晚期非小细胞肺癌的疗效。
J Cancer Res Clin Oncol. 2023 Dec;149(20):17987-17995. doi: 10.1007/s00432-023-05490-8. Epub 2023 Nov 17.
4
Pseudoprogression during successful rechallenge of immune checkpoint inhibitor in a NSCLC patient.免疫检查点抑制剂治疗成功后复发性非小细胞肺癌的假性进展。
Adv Respir Med. 2021;89(3):316-319. doi: 10.5603/ARM.a2021.0016.
5
The effect and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer.免疫检查点抑制剂在非小细胞肺癌中的再挑战的效果和安全性。
Jpn J Clin Oncol. 2019 Aug 1;49(8):762-765. doi: 10.1093/jjco/hyz066.
6
Efficacy and predictors of rechallenge with immune checkpoint inhibitors in non-small cell lung cancer.免疫检查点抑制剂在非小细胞肺癌中的再挑战疗效和预测因素。
Thorac Cancer. 2022 Feb;13(4):624-630. doi: 10.1111/1759-7714.14309. Epub 2022 Jan 6.
7
Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.晚期非小细胞肺癌患者中抗 PD-1 和抗 PD-L1 抗体免疫检查点抑制剂再挑战时的给药切换：病例系列和文献复习。
Thorac Cancer. 2020 Jul;11(7):1927-1933. doi: 10.1111/1759-7714.13483. Epub 2020 May 18.
8
Pembrolizumab rechallenge in squamous non-small-cell lung cancer and HIV-positivity: a case report.帕博利珠单抗在鳞状非小细胞肺癌合并 HIV 阳性患者中的再次挑战：一例报告。
Immunotherapy. 2021 Mar;13(4):277-281. doi: 10.2217/imt-2020-0180. Epub 2020 Nov 30.
9
Immune Checkpoint Inhibitor Rechallenge in Renal Cell Carcinoma: Current Evidence and Future Directions.肾细胞癌中免疫检查点抑制剂再激发：当前证据与未来方向
Cancers (Basel). 2023 Jun 13;15(12):3172. doi: 10.3390/cancers15123172.
10
Immune checkpoints related-LncRNAs can identify different subtypes of lung cancer and predict immunotherapy and prognosis.免疫检查点相关长链非编码 RNA 可鉴定不同亚型的肺癌，并预测免疫治疗和预后。
J Cancer Res Clin Oncol. 2022 Jul;148(7):1597-1612. doi: 10.1007/s00432-022-03940-3. Epub 2022 Mar 17.
引用本文的文献
1
The impact of immune-related adverse events on survival outcomes in a racially diverse population, with a focus on non-Hispanic Black patients.免疫相关不良事件对种族多样化人群生存结局的影响，重点关注非西班牙裔黑人患者。
Oncologist. 2025 Mar 10;30(3). doi: 10.1093/oncolo/oyae279.
2
Rechallenge with Anti-PD-1 Inhibitors in Patients with Recurrent Gynecologic Malignancies.抗 PD-1 抑制剂在复发性妇科恶性肿瘤患者中的再挑战。
Yonsei Med J. 2023 Oct;64(10):587-592. doi: 10.3349/ymj.2023.0063.
3
Efficacy and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer: A systematic review and meta-analysis.免疫检查点抑制剂在非小细胞肺癌中的再次治疗的疗效和安全性：系统评价和荟萃分析。
Thorac Cancer. 2023 Sep;14(25):2536-2547. doi: 10.1111/1759-7714.15063. Epub 2023 Aug 8.
4
Double Guard Efficiency and Safety-Overcoming Resistance to Immunotherapy by Blocking or Stimulating Several Immune Checkpoints in Non-Small Cell Lung Cancer Patients.双重保障疗效与安全性——通过阻断或刺激非小细胞肺癌患者的多个免疫检查点克服免疫治疗耐药性
Cancers (Basel). 2023 Jul 5;15(13):3499. doi: 10.3390/cancers15133499.
5
Immune Checkpoint Inhibitors for Solid Tumors in the Adjuvant Setting: Current Progress, Future Directions, and Role in Transplant Oncology.辅助治疗中实体瘤的免疫检查点抑制剂：当前进展、未来方向及在移植肿瘤学中的作用
Cancers (Basel). 2023 Feb 23;15(5):1433. doi: 10.3390/cancers15051433.
6
Advanced non-small-cell lung cancer: how to manage non-oncogene disease.晚期非小细胞肺癌：如何应对非致癌基因疾病。
Drugs Context. 2022 Jul 8;11. doi: 10.7573/dic.2022-2-4. eCollection 2022.
7
Review of Immune-Related Adverse Events (irAEs) in Non-Small-Cell Lung Cancer (NSCLC)-Their Incidence, Management, Multiorgan irAEs, and Rechallenge.非小细胞肺癌（NSCLC）中免疫相关不良事件（irAEs）的综述——其发生率、管理、多器官irAEs及再次激发
Biomedicines. 2022 Mar 28;10(4):790. doi: 10.3390/biomedicines10040790.
8
Multicenter Real-World Study on Effectiveness and Early Discontinuation Predictors in Patients With Non-small Cell Lung Cancer Receiving Nivolumab.多中心真实世界研究：纳武利尤单抗治疗非小细胞肺癌患者的有效性和早期停药预测因素。
Oncologist. 2022 Jun 8;27(6):e484-e493. doi: 10.1093/oncolo/oyac051.
9
Real-World Journey of Unresectable Stage III NSCLC Patients: Current Dilemmas for Disease Staging and Treatment.不可切除的 III 期非小细胞肺癌患者的真实世界历程：疾病分期与治疗的当前困境
J Clin Med. 2022 Mar 21;11(6):1738. doi: 10.3390/jcm11061738.
10
Molecular Imaging and the PD-L1 Pathway: From Bench to Clinic.分子成像与PD-L1通路：从实验室到临床
Front Oncol. 2021 Aug 23;11:698425. doi: 10.3389/fonc.2021.698425. eCollection 2021.
本文引用的文献
1
Durvalumab activity in previously treated patients who stopped durvalumab without disease progression.在未发生疾病进展的情况下停用 durvalumab 的经治患者中的 durvalumab 活性。
J Immunother Cancer. 2020 Aug;8(2). doi: 10.1136/jitc-2020-000650.
2
Immunotherapy rechallenge after nivolumab treatment in advanced non-small cell lung cancer in the real-world setting: A national data base analysis.免疫治疗重新挑战纳武利尤单抗治疗晚期非小细胞肺癌的真实世界研究：国家数据库分析。
Lung Cancer. 2020 Feb;140:99-106. doi: 10.1016/j.lungcan.2019.12.017. Epub 2019 Dec 31.
3
Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance.免疫治疗停药后的延迟免疫相关事件（DIRE）：远处自身免疫的诊断危害。
J Immunother Cancer. 2019 Jul 3;7(1):165. doi: 10.1186/s40425-019-0645-6.
4
Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis.免疫介导性结肠炎后免疫检查点抑制剂治疗的恢复。
J Clin Oncol. 2019 Oct 20;37(30):2738-2745. doi: 10.1200/JCO.19.00320. Epub 2019 Jun 4.
5
Chemotherapy in Combination With Immune Checkpoint Inhibitors for the First-Line Treatment of Patients With Advanced Non-small Cell Lung Cancer: A Systematic Review and Literature-Based Meta-Analysis.化疗联合免疫检查点抑制剂用于晚期非小细胞肺癌患者一线治疗的系统评价和基于文献的Meta分析
Front Oncol. 2019 Apr 16;9:264. doi: 10.3389/fonc.2019.00264. eCollection 2019.
6
Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC.非小细胞肺癌患者发生免疫相关不良事件后再次使用免疫治疗的安全性和疗效。
Cancer Immunol Res. 2018 Sep;6(9):1093-1099. doi: 10.1158/2326-6066.CIR-17-0755. Epub 2018 Jul 10.
7
CD103 Tumor-Resident CD8 T Cells Are Associated with Improved Survival in Immunotherapy-Naïve Melanoma Patients and Expand Significantly During Anti-PD-1 Treatment.肿瘤浸润 CD8 T 细胞与免疫治疗初治黑色素瘤患者的生存改善相关，并在抗 PD-1 治疗期间显著扩增。
Clin Cancer Res. 2018 Jul 1;24(13):3036-3045. doi: 10.1158/1078-0432.CCR-17-2257. Epub 2018 Mar 29.
8
Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study.纳武利尤单抗治疗经治晚期非小细胞肺癌的 5 年随访结果：CA209-003 研究结果。
J Clin Oncol. 2018 Jun 10;36(17):1675-1684. doi: 10.1200/JCO.2017.77.0412. Epub 2018 Mar 23.
9
Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma.帕博利珠单抗停药后转移性黑色素瘤患者持久完全缓解
J Clin Oncol. 2018 Jun 10;36(17):1668-1674. doi: 10.1200/JCO.2017.75.6270. Epub 2017 Dec 28.
10
Non-small cell lung cancer treatment (r)evolution: ten years of advances and more to come.非小细胞肺癌治疗的（变）革：十年进展及未来展望
Ecancermedicalscience. 2017 Nov 30;11:787. doi: 10.3332/ecancer.2017.787. eCollection 2017.
Zotero 插件